147 related articles for article (PubMed ID: 9496382)
1. Differences in docetaxel and paclitaxel activity in resistant tumor cells which express MRP: need of comparative clinical trials in resistant patients.
D'Incalci M
Ann Oncol; 1997 Dec; 8(12):1183-4. PubMed ID: 9496382
[No Abstract] [Full Text] [Related]
2. Comparative antitumor efficacy of docetaxel and paclitaxel in nude mice bearing human tumor xenografts that overexpress the multidrug resistance protein (MRP).
Vanhoefer U; Cao S; Harstrick A; Seeber S; Rustum YM
Ann Oncol; 1997 Dec; 8(12):1221-8. PubMed ID: 9496387
[TBL] [Abstract][Full Text] [Related]
3. Mechanisms of taxotere-related drug resistance in pancreatic carcinoma.
Liu B; Staren ED; Iwamura T; Appert HE; Howard JM
J Surg Res; 2001 Aug; 99(2):179-86. PubMed ID: 11469885
[TBL] [Abstract][Full Text] [Related]
4. Taxanes: a new class of antitumor agents.
Huizing MT; Misser VH; Pieters RC; ten Bokkel Huinink WW; Veenhof CH; Vermorken JB; Pinedo HM; Beijnen JH
Cancer Invest; 1995; 13(4):381-404. PubMed ID: 7627725
[TBL] [Abstract][Full Text] [Related]
5. Cytosine arabinoside (ara-C) resistance confers cross-resistance or collateral sensitivity to other classes of anti-leukemic drugs.
Martin-Aragon S; Mukherjee SK; Taylor BJ; Ivy SP; Fu CH; Ardi VC; Avramis VI
Anticancer Res; 2000; 20(1A):139-50. PubMed ID: 10769646
[TBL] [Abstract][Full Text] [Related]
6. In vitro antiproliferative activity of docetaxel (Taxotere), paclitaxel (Taxol) and cisplatin against human tumour and normal bone marrow cells.
Braakhuis BJ; Hill BT; Dietel M; Kelland LR; Aapro MS; Zoli W; Lelieveld P
Anticancer Res; 1994; 14(1A):205-8. PubMed ID: 7909419
[TBL] [Abstract][Full Text] [Related]
7. Taxane-induced apoptosis decompresses blood vessels and lowers interstitial fluid pressure in solid tumors: clinical implications.
Griffon-Etienne G; Boucher Y; Brekken C; Suit HD; Jain RK
Cancer Res; 1999 Aug; 59(15):3776-82. PubMed ID: 10446995
[TBL] [Abstract][Full Text] [Related]
8. Synthesis and cytotoxicity of 2alpha-amido docetaxel analogues.
Fang WS; Liu Y; Liu HY; Xu SF; Wang L; Fang QC
Bioorg Med Chem Lett; 2002 Jun; 12(11):1543-6. PubMed ID: 12031338
[TBL] [Abstract][Full Text] [Related]
9. Co-expression of several molecular mechanisms of multidrug resistance and their significance for paclitaxel cytotoxicity in human AML HL-60 cells.
Huang Y; Ibrado AM; Reed JC; Bullock G; Ray S; Tang C; Bhalla K
Leukemia; 1997 Feb; 11(2):253-7. PubMed ID: 9009089
[TBL] [Abstract][Full Text] [Related]
10. Chemistry and chemical biology of taxane anticancer agents.
Miller ML; Ojima I
Chem Rec; 2001; 1(3):195-211. PubMed ID: 11895119
[TBL] [Abstract][Full Text] [Related]
11. Effects of Taxotere on invasive potential and multidrug resistance phenotype in pancreatic carcinoma cell line SUIT-2.
Liu B; Staren E; Iwamura T; Appert H; Howard J
World J Gastroenterol; 2001 Feb; 7(1):143-8. PubMed ID: 11819752
[No Abstract] [Full Text] [Related]
12. Lack of thermal enhancement for taxanes in vitro.
Rietbroek RC; Katschinski DM; Reijers MH; Robins HI; Geerdink A; Tutsch K; d'Oleire F; Haveman J
Int J Hyperthermia; 1997; 13(5):525-33. PubMed ID: 9354937
[TBL] [Abstract][Full Text] [Related]
13. Comparison of paclitaxel and docetaxel (Taxotere) in gynecologic and breast cancer cell lines with the ATP-cell viability assay.
Untch M; Untch A; Sevin BU; Angioli R; Perras JP; Koechli O; Averette HE
Anticancer Drugs; 1994 Feb; 5(1):24-30. PubMed ID: 7910494
[TBL] [Abstract][Full Text] [Related]
14. The taxoids: paclitaxel and docetaxel.
Gelmon K
Lancet; 1994 Nov; 344(8932):1267-72. PubMed ID: 7967989
[No Abstract] [Full Text] [Related]
15. Differential impact of Raf-1 kinase activity on tumor cell resistance to paclitaxel and docetaxel.
Britten RA; Klein K
Anticancer Drugs; 2000 Jul; 11(6):439-43. PubMed ID: 11001384
[TBL] [Abstract][Full Text] [Related]
16. Docetaxel in breast cancer and a rationale for combination therapy.
Hortobágyi G
Oncology (Williston Park); 1997 Jun; 11(6 Suppl 6):11-5. PubMed ID: 9213321
[TBL] [Abstract][Full Text] [Related]
17. MDR 1 activation is the predominant resistance mechanism selected by vinblastine in MES-SA cells.
Chen GK; Durán GE; Mangili A; Beketic-Oreskovic L; Sikic BI
Br J Cancer; 2000 Oct; 83(7):892-8. PubMed ID: 10970691
[TBL] [Abstract][Full Text] [Related]
18. The scientific rationale for developing taxoids.
Aapro M
Anticancer Drugs; 1996 Aug; 7 Suppl 2():33-6. PubMed ID: 8862709
[TBL] [Abstract][Full Text] [Related]
19. The taxoids: paclitaxel (Taxol) and docetaxel (Taxotere).
Pazdur R; Kudelka AP; Kavanagh JJ; Cohen PR; Raber MN
Cancer Treat Rev; 1993 Oct; 19(4):351-86. PubMed ID: 8106152
[TBL] [Abstract][Full Text] [Related]
20. Docetaxel induced gene expression patterns in head and neck squamous cell carcinoma using cDNA microarray and PowerBlot.
Yoo GH; Piechocki MP; Ensley JF; Nguyen T; Oliver J; Meng H; Kewson D; Shibuya TY; Lonardo F; Tainsky MA
Clin Cancer Res; 2002 Dec; 8(12):3910-21. PubMed ID: 12473607
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
